<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00289913</url>
  </required_header>
  <id_info>
    <org_study_id>V251-068</org_study_id>
    <secondary_id>2005_076</secondary_id>
    <nct_id>NCT00289913</nct_id>
  </id_info>
  <brief_title>Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)</brief_title>
  <official_title>An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of VAQTA™ Given Concomitantly With PedvaxHIB™ and Infanrix™ in Healthy Children 15 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This two-stage study evaluates the immunogenicity, safety, and tolerability of the
      administration of VAQTA™ (Hepatitis A Vaccine, Inactivated) concomitantly with PedvaxHIB™
      (Haemophilus B Conjugate Vaccine [Meningococcal Protein Conjugate]) and Infanrix™ (Diphtheria
      and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, GlaxoSmithKline) versus the
      administration of VAQTA™ in healthy children 15 months of age at study entry.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In stage I, VAQTA™ given concomitantly with Infanrix™ and/or PedvaxHIB™ was evaluated.

      In stage 2: Two (2) doses of the VAQTA™ vaccine were administered at least 6 months apart.
      Safety data was collected after each dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seropositivity Rate (SPR) to Hepatitis A</measure>
    <time_frame>4 weeks after dose 2 of VAQTA™</time_frame>
    <description>SPR is the percent of participants with Hepatitis A antibody titers &gt;= 10 milli-International Units/milliliter (mIU/mL), 4 weeks after dose 2 of VAQTA™ regardless of their initial serostatus. Antibody titers to Hepatitis A virus (HAV) were detected in participants' serum samples using an Enzyme Immunoassay (EIA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response Rate to Haemophilus Influenzae Type b (Hib)</measure>
    <time_frame>4 weeks postvaccination with PedvaxHIB™</time_frame>
    <description>Antibodies to the Hib capsular polysaccharide (polyribosylribitol phosphate [PRP]) are assessed in participants serum using radioimmunoassay (RIA). The limit of detection (LOD) for the RIA is 6.60 ng/mL.
The antibody response rate is defined as the percentage of participants with anti-PRP titers &gt;1.0 mcg/mL, 4 weeks postvaccination with PedvaxHIB™.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AE)</measure>
    <time_frame>Days 1 to 14 after any dose of VAQTA™ for systemic AEs, and Days 1 to 5 after any dose of VAQTA™ for injection-site AEs</time_frame>
    <description>Systemic and injection site AEs were collected from participants receiving
VAQTA™ concomitantly with Infanrix™ and PedvaxHIB™ or PedvaxHIB™ (Stage I)
VAQTA™ non-concomitantly with Infanrix™ and PedvaxHIB™ or PedvaxHIB™ (Stage I)
VAQTA™ administered alone (Stage II)
Safety data was collected on a standardized Vaccination Report Card (VRC)
following each dose. Participants returned the VRC after the safety follow-up period for each dose of VAQTA™. AEs determined by the investigator to be possibly, probably or definitely related to the vaccine are reported as Vaccine-related AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) to Antibodies for the Pertussis Toxin (PT), Pertussis Filamentous Hemagglutinin Antibody (FHA), and Pertactin (PRN) Components of Infanrix™</measure>
    <time_frame>4 weeks postvaccination with Infanrix™</time_frame>
    <description>GMTs for antibodies to PT, FHA, and PRN were measured in serum samples of participants vaccinated with Infanrix™.
IgG antibodies to PT were assessed using the anti-pertussis toxin enzyme-linked immunosorbent assay (anti-PT ELISA), with the LOD of 2.4 ELU/mL.
IgG antibodies to FHA were assessed using the anti-pertussis filamentous hemagglutinin enzyme-linked immunosorbent assay (anti-FHA ELISA), with the LOD of 2.0 ELU/mL.
IgG antibodies to PRN were assessed using the anti-pertussis pertactin enzyme-linked immunosorbent assay (anti-PRN ELISA), with the LOD of 3.3 ELU/mL.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1274</enrollment>
  <condition>Hepatitis A Virus</condition>
  <arm_group>
    <arm_group_label>VAQTA™, PedvaxHIB™ and Infanrix™/VAQTA™ (Stage 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: VAQTA™ (first dose), PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.
Week 24: The second dose of VAQTA™ was administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PedvaxHIB™ and Infanrix™/VAQTA™/VAQTA™ (Stage 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.
Week 4: The first dose of VAQTA™ was administered.
Week 28: The second dose of VAQTA™ was administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VAQTA™, PedvaxHIB™/VAQTA™ (Stage 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: VAQTA™ (first dose) and PedvaxHIB™ were administered concomitantly at different injection sites.
Week 24: The second dose of VAQTA™ was administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PedvaxHIB™/VAQTA™/VAQTA™ (Stage 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: PedvaxHIB™ was administered.
Week 4: The first dose of VAQTA™ was administered.
Week 28: The second dose of VAQTA™ was administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VAQTA™/VAQTA™ (Stage 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: The first dose of VAQTA™ was administered.
Week 24: The second dose of VAQTA™ was administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: VAQTA™</intervention_name>
    <description>VAQTA™ (Hepatitis A Vaccine, Inactivated).
Two intramuscular 0.5-mL doses of VAQTA™ were administered 24 weeks apart, with the second dose being administered prior to 24 months of age.</description>
    <arm_group_label>VAQTA™, PedvaxHIB™ and Infanrix™/VAQTA™ (Stage 1)</arm_group_label>
    <arm_group_label>PedvaxHIB™ and Infanrix™/VAQTA™/VAQTA™ (Stage 1)</arm_group_label>
    <arm_group_label>VAQTA™, PedvaxHIB™/VAQTA™ (Stage 1)</arm_group_label>
    <arm_group_label>PedvaxHIB™/VAQTA™/VAQTA™ (Stage 1)</arm_group_label>
    <arm_group_label>VAQTA™/VAQTA™ (Stage 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Infanrix™</intervention_name>
    <description>Infanrix™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis
Vaccine Adsorbed, GlaxoSmithKline).
One intramuscular 0.5-mL injection of Infanrix™ was administered at the first study visit.</description>
    <arm_group_label>VAQTA™, PedvaxHIB™ and Infanrix™/VAQTA™ (Stage 1)</arm_group_label>
    <arm_group_label>PedvaxHIB™ and Infanrix™/VAQTA™/VAQTA™ (Stage 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: PedvaxHIB™</intervention_name>
    <description>PedvaxHIB™ (Haemophilus B Conjugate Vaccine [Meningococcal Protein Conjugate]).
One intramuscular 0.5-mL injection of PedvaxHIB™ was administered at the first study visit.</description>
    <arm_group_label>VAQTA™, PedvaxHIB™ and Infanrix™/VAQTA™ (Stage 1)</arm_group_label>
    <arm_group_label>PedvaxHIB™ and Infanrix™/VAQTA™/VAQTA™ (Stage 1)</arm_group_label>
    <arm_group_label>VAQTA™, PedvaxHIB™/VAQTA™ (Stage 1)</arm_group_label>
    <arm_group_label>PedvaxHIB™/VAQTA™/VAQTA™ (Stage 1)</arm_group_label>
    <other_name>One intramuscular 0.5-mL injection of PedvaxHIB™ was administered to all subjects at the first study</other_name>
    <other_name>visit in all treatment groups in the study.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage 1) Healthy males and females 15 months of age with no active liver disease and a
             negative history of hepatitis A who have been vaccinated against Haemophilus
             influenzae type b (Hib), diphtheria, tetanus, and pertussis diseases

          -  Stage 2) Healthy males and females 12 to 17 months of age with no active liver disease
             and a negative history of hepatitis A

        Exclusion Criteria:

          -  Stage 1) Males and females previously vaccinated with hepatitis A vaccine, any immune
             deficiency, a history of allergy to any of the vaccine components, a history of
             seizure disorder or a neurologic disorder that would contraindicate pertussis vaccine,
             or a bleeding disorder

          -  Stage 2) Males and females previously vaccinated with hepatitis A vaccine, any immune
             deficiency, a history of allergy to any of the vaccine components, or a history of
             bleeding disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>17 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <results_reference>
    <citation>Petrecz M, Ramsey KP, Stek JE, Martin JC, Klopfer SO, Kuter B, Schödel FP, Lee AW. Concomitant use of VAQTA with PedvaxHIB and Infanrix in 12 to 17 month old children. Hum Vaccin Immunother. 2016;12(2):503-11. doi: 10.1080/21645515.2015.1080395.</citation>
    <PMID>26308112</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2006</study_first_submitted>
  <study_first_submitted_qc>February 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2006</study_first_posted>
  <results_first_submitted>June 9, 2011</results_first_submitted>
  <results_first_submitted_qc>June 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 7, 2011</results_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis A virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In Stage I, a total of 620 participants were randomized to receive study vaccinations. However for 3 participants, the Health Insurance Portability and Accountability Act (HIPAA) and/or Informed Consent Form was not signed by the parents in error. Therefore a total of 617 participants were included in Stage I. 654 participants started Stage II.</recruitment_details>
      <pre_assignment_details>For this study: Visit 1 was on Day 1 (for Stage I and Stage II). Visit 2 was at Week 4 (Stage I) and Week 2 (Stage II). Visit 3 was at Week 24/Week 28 (Stage I) and Week 24 (Stage II). Visit 4 was at Week 28/Week 32 (Stage I) and Week 26 (Stage II). For safety, participants were followed for 14 days after each vaccination (safety follow-up [F/U]).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>VAQTA™, PedvaxHIB™ and Infanrix™/ VAQTA™ (Stage 1)</title>
          <description>Day 1: VAQTA™ (first dose), PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.
Week 24: The second dose of VAQTA™ was administered.</description>
        </group>
        <group group_id="P2">
          <title>PedvaxHIB™ and Infanrix™/ VAQTA™/ VAQTA™ (Stage 1)</title>
          <description>Day 1: PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.
Week 4: The first dose of VAQTA™ was administered.
Week 28: The second dose of VAQTA™ was administered.</description>
        </group>
        <group group_id="P3">
          <title>VAQTA™, PedvaxHIB™/ VAQTA™ (Stage 1)</title>
          <description>Day 1: VAQTA™ (first dose) and PedvaxHIB™ were administered concomitantly at different injection sites.
Week 24: The second dose of VAQTA™ was administered.</description>
        </group>
        <group group_id="P4">
          <title>PedvaxHIB™/ VAQTA™/ VAQTA™ (Stage 1)</title>
          <description>Day 1: PedvaxHIB™ was administered.
Week 4: The first dose of VAQTA™ was administered.
Week 28: The second dose of VAQTA™ was administered.</description>
        </group>
        <group group_id="P5">
          <title>VAQTA™/ VAQTA™ (Stage 2)</title>
          <description>Day 1: The first dose of VAQTA™ was administered.
Week 24: The second dose of VAQTA™ was administered.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Visit 1 (Stage I and Stage II)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="151"/>
                <participants group_id="P3" count="159"/>
                <participants group_id="P4" count="152"/>
                <participants group_id="P5" count="654">Participants were enrolled during Stage II.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="135"/>
                <participants group_id="P3" count="150"/>
                <participants group_id="P4" count="141"/>
                <participants group_id="P5" count="645"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol deviation during safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost during safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent during safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved during safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons during safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation after safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost after safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent after safety F/U]</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons after safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Visit 2 (Stage I and Stage II)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="135"/>
                <participants group_id="P3" count="150"/>
                <participants group_id="P4" count="141"/>
                <participants group_id="P5" count="645">No vaccine administered at Visit 2 (Stage II), therefore there was no safety F/U period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="140"/>
                <participants group_id="P4" count="135"/>
                <participants group_id="P5" count="605"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="40"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol deviation during safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost during safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject moved during safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent during safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons during safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation after safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost after safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent after safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons after safety F/U]</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation (Stage II)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost (Stage II)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved (Stage II)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent (Stage II)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons (Stage II)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Visit 3 (Stage I and Stage II)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="140"/>
                <participants group_id="P4" count="135"/>
                <participants group_id="P5" count="605"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="106"/>
                <participants group_id="P3" count="138"/>
                <participants group_id="P4" count="131"/>
                <participants group_id="P5" count="597"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol deviation during safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost during safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent during safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons during safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost after safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent after safety F/U]</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved after safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons after safety F/U</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Visit 4 (Stage I and Stage II)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="106"/>
                <participants group_id="P3" count="138"/>
                <participants group_id="P4" count="131"/>
                <participants group_id="P5" count="597"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="106"/>
                <participants group_id="P3" count="138"/>
                <participants group_id="P4" count="131"/>
                <participants group_id="P5" count="597"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VAQTA™, PedvaxHIB™ and Infanrix™/ VAQTA™ (Stage 1)</title>
          <description>Day 1: VAQTA™ (first dose), PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.
Week 24: The second dose of VAQTA™ was administered.</description>
        </group>
        <group group_id="B2">
          <title>PedvaxHIB™ and Infanrix™/ VAQTA™/ VAQTA™ (Stage 1)</title>
          <description>Day 1: PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.
Week 4: The first dose of VAQTA™ was administered.
Week 28: The second dose of VAQTA™ was administered.</description>
        </group>
        <group group_id="B3">
          <title>VAQTA™, PedvaxHIB™/ VAQTA™ (Stage 1)</title>
          <description>Day 1: VAQTA™ (first dose) and PedvaxHIB™ were administered concomitantly at different injection sites.
Week 24: The second dose of VAQTA™ was administered.</description>
        </group>
        <group group_id="B4">
          <title>PedvaxHIB™/ VAQTA™/ VAQTA™ (Stage 1)</title>
          <description>Day 1: PedvaxHIB™ was administered.
Week 4: The first dose of VAQTA™ was administered.
Week 28: The second dose of VAQTA™ was administered.</description>
        </group>
        <group group_id="B5">
          <title>VAQTA™/ VAQTA™ (Stage 2)</title>
          <description>Day 1: The first dose of VAQTA™ was administered.
Week 24: The second dose of VAQTA™ was administered.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="155"/>
            <count group_id="B2" value="151"/>
            <count group_id="B3" value="159"/>
            <count group_id="B4" value="152"/>
            <count group_id="B5" value="654"/>
            <count group_id="B6" value="1271"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Months between the birthdate and consent date.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 12 and 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="159"/>
                    <measurement group_id="B4" value="152"/>
                    <measurement group_id="B5" value="654"/>
                    <measurement group_id="B6" value="1271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="73"/>
                    <measurement group_id="B5" value="319"/>
                    <measurement group_id="B6" value="603"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="79"/>
                    <measurement group_id="B5" value="335"/>
                    <measurement group_id="B6" value="668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seropositivity Rate (SPR) to Hepatitis A</title>
        <description>SPR is the percent of participants with Hepatitis A antibody titers &gt;= 10 milli-International Units/milliliter (mIU/mL), 4 weeks after dose 2 of VAQTA™ regardless of their initial serostatus. Antibody titers to Hepatitis A virus (HAV) were detected in participants' serum samples using an Enzyme Immunoassay (EIA).</description>
        <time_frame>4 weeks after dose 2 of VAQTA™</time_frame>
        <population>The per-protocol population, which consisted of all Stage I participants who received vaccinations within the specified day ranges, completed appropriate follow-up, and were without any pre-specified protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>VAQTA™, PedvaxHIB™ and Infanrix™/ VAQTA™ (Stage 1)</title>
            <description>Day 1: VAQTA™ (first dose), PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.
Week 24: The second dose of VAQTA™ was administered.</description>
          </group>
          <group group_id="O2">
            <title>PedvaxHIB™ and Infanrix™/ VAQTA™/ VAQTA™ (Stage 1)</title>
            <description>Day 1: PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.
Week 4: The first dose of VAQTA™ was administered.
Week 28: The second dose of VAQTA™ was administered.</description>
          </group>
          <group group_id="O3">
            <title>VAQTA™, PedvaxHIB™/ VAQTA™ (Stage 1)</title>
            <description>Day 1: VAQTA™ (first dose) and PedvaxHIB™ were administered concomitantly at different injection sites.
Week 24: The second dose of VAQTA™ was administered.</description>
          </group>
          <group group_id="O4">
            <title>PedvaxHIB™/ VAQTA™/ VAQTA™ (Stage 1)</title>
            <description>Day 1: PedvaxHIB™ was administered.
Week 4: The first dose of VAQTA™ was administered.
Week 28: The second dose of VAQTA™ was administered.</description>
          </group>
          <group group_id="O5">
            <title>VAQTA™/ VAQTA™ (Stage 2)</title>
            <description>Day 1: The first dose of VAQTA™ was administered.
Week 24: The second dose of VAQTA™ was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Seropositivity Rate (SPR) to Hepatitis A</title>
          <description>SPR is the percent of participants with Hepatitis A antibody titers &gt;= 10 milli-International Units/milliliter (mIU/mL), 4 weeks after dose 2 of VAQTA™ regardless of their initial serostatus. Antibody titers to Hepatitis A virus (HAV) were detected in participants' serum samples using an Enzyme Immunoassay (EIA).</description>
          <population>The per-protocol population, which consisted of all Stage I participants who received vaccinations within the specified day ranges, completed appropriate follow-up, and were without any pre-specified protocol violations.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="114"/>
                <count group_id="O4" value="105"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.2" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="95.4" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="96.8" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="96.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response Rate to Haemophilus Influenzae Type b (Hib)</title>
        <description>Antibodies to the Hib capsular polysaccharide (polyribosylribitol phosphate [PRP]) are assessed in participants serum using radioimmunoassay (RIA). The limit of detection (LOD) for the RIA is 6.60 ng/mL.
The antibody response rate is defined as the percentage of participants with anti-PRP titers &gt;1.0 mcg/mL, 4 weeks postvaccination with PedvaxHIB™.</description>
        <time_frame>4 weeks postvaccination with PedvaxHIB™</time_frame>
        <population>The per-protocol population, which consisted of all Stage I participants who received vaccinations within the specified day ranges, completed appropriate follow-up, and were without any pre-specified protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>VAQTA™, PedvaxHIB™ and Infanrix™/ VAQTA™ (Stage 1)</title>
            <description>Day 1: VAQTA™ (first dose), PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.
Week 24: The second dose of VAQTA™ was administered.</description>
          </group>
          <group group_id="O2">
            <title>PedvaxHIB™ and Infanrix™/ VAQTA™/ VAQTA™ (Stage 1)</title>
            <description>Day 1: PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.
Week 4: The first dose of VAQTA™ was administered.
Week 28: The second dose of VAQTA™ was administered.</description>
          </group>
          <group group_id="O3">
            <title>VAQTA™, PedvaxHIB™/ VAQTA™ (Stage 1)</title>
            <description>Day 1: VAQTA™ (first dose) and PedvaxHIB™ were administered concomitantly at different injection sites.
Week 24: The second dose of VAQTA™ was administered.</description>
          </group>
          <group group_id="O4">
            <title>PedvaxHIB™/ VAQTA™/ VAQTA™ (Stage 1)</title>
            <description>Day 1: PedvaxHIB™ was administered.
Week 4: The first dose of VAQTA™ was administered.
Week 28: The second dose of VAQTA™ was administered.</description>
          </group>
          <group group_id="O5">
            <title>VAQTA™/ VAQTA™ (Stage 2)</title>
            <description>Day 1: The first dose of VAQTA™ was administered.
Week 24: The second dose of VAQTA™ was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response Rate to Haemophilus Influenzae Type b (Hib)</title>
          <description>Antibodies to the Hib capsular polysaccharide (polyribosylribitol phosphate [PRP]) are assessed in participants serum using radioimmunoassay (RIA). The limit of detection (LOD) for the RIA is 6.60 ng/mL.
The antibody response rate is defined as the percentage of participants with anti-PRP titers &gt;1.0 mcg/mL, 4 weeks postvaccination with PedvaxHIB™.</description>
          <population>The per-protocol population, which consisted of all Stage I participants who received vaccinations within the specified day ranges, completed appropriate follow-up, and were without any pre-specified protocol violations.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="93.4" upper_limit="99.8"/>
                    <measurement group_id="O2" value="97.0" lower_limit="91.4" upper_limit="99.4"/>
                    <measurement group_id="O3" value="97.3" lower_limit="92.2" upper_limit="99.4"/>
                    <measurement group_id="O4" value="97.2" lower_limit="92.2" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AE)</title>
        <description>Systemic and injection site AEs were collected from participants receiving
VAQTA™ concomitantly with Infanrix™ and PedvaxHIB™ or PedvaxHIB™ (Stage I)
VAQTA™ non-concomitantly with Infanrix™ and PedvaxHIB™ or PedvaxHIB™ (Stage I)
VAQTA™ administered alone (Stage II)
Safety data was collected on a standardized Vaccination Report Card (VRC)
following each dose. Participants returned the VRC after the safety follow-up period for each dose of VAQTA™. AEs determined by the investigator to be possibly, probably or definitely related to the vaccine are reported as Vaccine-related AE.</description>
        <time_frame>Days 1 to 14 after any dose of VAQTA™ for systemic AEs, and Days 1 to 5 after any dose of VAQTA™ for injection-site AEs</time_frame>
        <population>Participants administered at least one dose of vaccine, for whom follow-up was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant VAQTA™ With Infanrix™ and PedvaxHIB™ or PedvaxHIB™</title>
            <description>All participants receiving VAQTA™ Concomitantly with Infanrix™ and PedvaxHIB™ or PedvaxHIB™ were pooled for safety analysis; and includes participants from Groups 1: VAQTA™, PedvaxHIB™ and Infanrix™/VAQTA™ (Stage 1); and Group 3: VAQTA™, PedvaxHIB™/VAQTA™ (Stage 1).</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant VAQTA™ Separate From Infanrix™ and PedvaxHIB™</title>
            <description>All participants receiving VAQTA™ non-concomitantly with Infanrix™ and PedvaxHIB™ or PedvaxHIB™ were pooled for safety analysis; and includes participants from Groups 2: PedvaxHIB™ and Infanrix™/VAQTA™/VAQTA™ (Stage 1); and Group 4: PedvaxHIB™/VAQTA™/VAQTA™ (Stage 1).</description>
          </group>
          <group group_id="O3">
            <title>VAQTA™/VAQTA™</title>
            <description>All participants receiving VAQTA™ alone (from Stage II) on Day 1 and Day 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AE)</title>
          <description>Systemic and injection site AEs were collected from participants receiving
VAQTA™ concomitantly with Infanrix™ and PedvaxHIB™ or PedvaxHIB™ (Stage I)
VAQTA™ non-concomitantly with Infanrix™ and PedvaxHIB™ or PedvaxHIB™ (Stage I)
VAQTA™ administered alone (Stage II)
Safety data was collected on a standardized Vaccination Report Card (VRC)
following each dose. Participants returned the VRC after the safety follow-up period for each dose of VAQTA™. AEs determined by the investigator to be possibly, probably or definitely related to the vaccine are reported as Vaccine-related AE.</description>
          <population>Participants administered at least one dose of vaccine, for whom follow-up was available.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="647"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With no AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With one or more AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239"/>
                    <measurement group_id="O2" value="170"/>
                    <measurement group_id="O3" value="466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>---injection-site AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="116"/>
                    <measurement group_id="O3" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>---sytemic AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With vaccine-related (VR) AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="129"/>
                    <measurement group_id="O3" value="328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>---injection-site AE (VR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                    <measurement group_id="O2" value="116"/>
                    <measurement group_id="O3" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>---sytemic AE (VR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With serious AE (VR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Who died</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Who discontinued due to AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Who discontinued due to serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) to Antibodies for the Pertussis Toxin (PT), Pertussis Filamentous Hemagglutinin Antibody (FHA), and Pertactin (PRN) Components of Infanrix™</title>
        <description>GMTs for antibodies to PT, FHA, and PRN were measured in serum samples of participants vaccinated with Infanrix™.
IgG antibodies to PT were assessed using the anti-pertussis toxin enzyme-linked immunosorbent assay (anti-PT ELISA), with the LOD of 2.4 ELU/mL.
IgG antibodies to FHA were assessed using the anti-pertussis filamentous hemagglutinin enzyme-linked immunosorbent assay (anti-FHA ELISA), with the LOD of 2.0 ELU/mL.
IgG antibodies to PRN were assessed using the anti-pertussis pertactin enzyme-linked immunosorbent assay (anti-PRN ELISA), with the LOD of 3.3 ELU/mL.</description>
        <time_frame>4 weeks postvaccination with Infanrix™</time_frame>
        <population>The per-protocol population, which consisted of all Stage I participants who received vaccinations within the specified day ranges, completed appropriate follow-up, and were without any pre-specified protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>VAQTA™, PedvaxHIB™ and Infanrix™/ VAQTA™ (Stage 1)</title>
            <description>Day 1: VAQTA™ (first dose), PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.
Week 24: The second dose of VAQTA™ was administered.</description>
          </group>
          <group group_id="O2">
            <title>PedvaxHIB™ and Infanrix™/ VAQTA™/ VAQTA™ (Stage 1)</title>
            <description>Day 1: PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.
Week 4: The first dose of VAQTA™ was administered.
Week 28: The second dose of VAQTA™ was administered.</description>
          </group>
          <group group_id="O3">
            <title>VAQTA™, PedvaxHIB™/ VAQTA™ (Stage 1)</title>
            <description>Day 1: VAQTA™ (first dose) and PedvaxHIB™ were administered concomitantly at different injection sites.
Week 24: The second dose of VAQTA™ was administered.</description>
          </group>
          <group group_id="O4">
            <title>PedvaxHIB™/ VAQTA™/ VAQTA™ (Stage 1)</title>
            <description>Day 1: PedvaxHIB™ was administered.
Week 4: The first dose of VAQTA™ was administered.
Week 28: The second dose of VAQTA™ was administered.</description>
          </group>
          <group group_id="O5">
            <title>VAQTA™/ VAQTA™ (Stage 2)</title>
            <description>Day 1: The first dose of VAQTA™ was administered.
Week 24: The second dose of VAQTA™ was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) to Antibodies for the Pertussis Toxin (PT), Pertussis Filamentous Hemagglutinin Antibody (FHA), and Pertactin (PRN) Components of Infanrix™</title>
          <description>GMTs for antibodies to PT, FHA, and PRN were measured in serum samples of participants vaccinated with Infanrix™.
IgG antibodies to PT were assessed using the anti-pertussis toxin enzyme-linked immunosorbent assay (anti-PT ELISA), with the LOD of 2.4 ELU/mL.
IgG antibodies to FHA were assessed using the anti-pertussis filamentous hemagglutinin enzyme-linked immunosorbent assay (anti-FHA ELISA), with the LOD of 2.0 ELU/mL.
IgG antibodies to PRN were assessed using the anti-pertussis pertactin enzyme-linked immunosorbent assay (anti-PRN ELISA), with the LOD of 3.3 ELU/mL.</description>
          <population>The per-protocol population, which consisted of all Stage I participants who received vaccinations within the specified day ranges, completed appropriate follow-up, and were without any pre-specified protocol violations.</population>
          <units>ELISA units per mL (ELU/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pertussis PT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2" lower_limit="57.4" upper_limit="83.5"/>
                    <measurement group_id="O2" value="51.7" lower_limit="41.5" upper_limit="64.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis FHA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.8" lower_limit="215.3" upper_limit="299.2"/>
                    <measurement group_id="O2" value="249.2" lower_limit="200.6" upper_limit="309.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333.5" lower_limit="267.3" upper_limit="416.1"/>
                    <measurement group_id="O2" value="358.5" lower_limit="282.7" upper_limit="454.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>VAQTA™, PedvaxHIB™ and Infanrix™/ VAQTA™ (Stage 1)</title>
          <description>Day 1: VAQTA™ (first dose), PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.
Week 24: The second dose of VAQTA™ was administered.</description>
        </group>
        <group group_id="E2">
          <title>PedvaxHIB™ and Infanrix™/ VAQTA™/ VAQTA™ (Stage 1)</title>
          <description>Day 1: PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.
Week 4: The first dose of VAQTA™ was administered.
Week 28: The second dose of VAQTA™ was administered.</description>
        </group>
        <group group_id="E3">
          <title>VAQTA™, PedvaxHIB™/ VAQTA™ (Stage 1)</title>
          <description>Day 1: VAQTA™ (first dose) and PedvaxHIB™ were administered concomitantly at different injection sites.
Week 24: The second dose of VAQTA™ was administered.</description>
        </group>
        <group group_id="E4">
          <title>PedvaxHIB™/ VAQTA™/ VAQTA™ (Stage I)</title>
          <description>Day 1: PedvaxHIB™ was administered.
Week 4: The first dose of VAQTA™ was administered.
Week 28: The second dose of VAQTA™ was administered.</description>
        </group>
        <group group_id="E5">
          <title>VAQTA™/ VAQTA™ (Stage 2)</title>
          <description>Day 1: The first dose of VAQTA™ was administered.
Week 24: The second dose of VAQTA™ was administered.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LYMPHADENITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FOREIGN BODY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="123" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="88" subjects_at_risk="146"/>
                <counts group_id="E5" subjects_affected="426" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="150"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="145"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="152"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="146"/>
                <counts group_id="E5" events="54" subjects_affected="50" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>TEETHING</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="145"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="146"/>
                <counts group_id="E5" events="69" subjects_affected="56" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="150"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="152"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="146"/>
                <counts group_id="E5" events="31" subjects_affected="27" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" events="62" subjects_affected="48" subjects_at_risk="150"/>
                <counts group_id="E2" events="39" subjects_affected="30" subjects_at_risk="145"/>
                <counts group_id="E3" events="55" subjects_affected="42" subjects_at_risk="152"/>
                <counts group_id="E4" events="58" subjects_affected="43" subjects_at_risk="146"/>
                <counts group_id="E5" events="174" subjects_affected="139" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" events="98" subjects_affected="75" subjects_at_risk="150"/>
                <counts group_id="E2" events="54" subjects_affected="40" subjects_at_risk="145"/>
                <counts group_id="E3" events="83" subjects_affected="62" subjects_at_risk="152"/>
                <counts group_id="E4" events="71" subjects_affected="55" subjects_at_risk="146"/>
                <counts group_id="E5" events="264" subjects_affected="203" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>INJECTION SITE SWELLING</sub_title>
                <counts group_id="E1" events="42" subjects_affected="36" subjects_at_risk="150"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="145"/>
                <counts group_id="E3" events="30" subjects_affected="26" subjects_at_risk="152"/>
                <counts group_id="E4" events="30" subjects_affected="26" subjects_at_risk="146"/>
                <counts group_id="E5" events="88" subjects_affected="73" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" events="35" subjects_affected="28" subjects_at_risk="150"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="145"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="152"/>
                <counts group_id="E4" events="14" subjects_affected="11" subjects_at_risk="146"/>
                <counts group_id="E5" events="102" subjects_affected="79" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="58" subjects_affected="43" subjects_at_risk="150"/>
                <counts group_id="E2" events="28" subjects_affected="24" subjects_at_risk="145"/>
                <counts group_id="E3" events="47" subjects_affected="42" subjects_at_risk="152"/>
                <counts group_id="E4" events="24" subjects_affected="23" subjects_at_risk="146"/>
                <counts group_id="E5" events="123" subjects_affected="106" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="150"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="145"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="152"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="146"/>
                <counts group_id="E5" events="19" subjects_affected="19" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="152"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="146"/>
                <counts group_id="E5" events="39" subjects_affected="38" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="150"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E5" events="12" subjects_affected="10" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="145"/>
                <counts group_id="E3" events="25" subjects_affected="23" subjects_at_risk="152"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="146"/>
                <counts group_id="E5" events="69" subjects_affected="65" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="150"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="145"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="152"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="146"/>
                <counts group_id="E5" events="50" subjects_affected="48" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="150"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="145"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="152"/>
                <counts group_id="E4" events="10" subjects_affected="6" subjects_at_risk="146"/>
                <counts group_id="E5" events="65" subjects_affected="57" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. SPONSOR review can be expedited to meet publication guidelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Late Stage Development Group Leader</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

